Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2012 1
2013 3
2016 2
2017 2
2018 4
2019 1
2020 3
2021 8
2022 10
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems.
Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Madamsetty VS, et al. Among authors: nabavi n. ACS Biomater Sci Eng. 2022 May 9;8(5):1763-1790. doi: 10.1021/acsbiomaterials.2c00026. Epub 2022 Apr 19. ACS Biomater Sci Eng. 2022. PMID: 35439408 Review.
Doxorubicin-loaded micelles in tumor cell-specific chemotherapy.
Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W, Ertas YN. Almajidi YQ, et al. Among authors: nabavi n. Environ Res. 2023 Jun 15;227:115722. doi: 10.1016/j.envres.2023.115722. Epub 2023 Mar 21. Environ Res. 2023. PMID: 36948284 Review.
Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.
Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, Taheriazam A, Alexiou A, Papadakis M, Tan SC. Hashemi M, et al. Among authors: nabavi n. Cell Mol Biol Lett. 2023 Apr 21;28(1):33. doi: 10.1186/s11658-023-00438-9. Cell Mol Biol Lett. 2023. PMID: 37085753 Free PMC article. Review.
Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.
Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M. Hashemi M, et al. Among authors: nabavi n. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166714. doi: 10.1016/j.bbadis.2023.166714. Epub 2023 Apr 5. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37028606 Review.
Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy.
Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, Karimi F, Samaei SS, Rezaee A, Rahmanian P, Khorrami R, Salimimoghadam S, Nabavi N, Zou R, Sethi G, Rashidi M, Hushmandi K. Zandieh MA, et al. Among authors: nabavi n. Biomed Pharmacother. 2023 Oct;166:115283. doi: 10.1016/j.biopha.2023.115283. Epub 2023 Aug 9. Biomed Pharmacother. 2023. PMID: 37567073 Free article. Review.
PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S, Nikpanjeh N, Rezaee A, Gholami S, Hashemipour R, Biavarz N, Yousefi F, Tashakori A, Salmani F, Rajabi R, Khorrami R, Nabavi N, Ren J, Salimimoghadam S, Rashidi M, Zandieh MA, Hushmandi K, Wang Y. Rezaei S, et al. Among authors: nabavi n. Eur J Pharmacol. 2023 Sep 15;955:175909. doi: 10.1016/j.ejphar.2023.175909. Epub 2023 Jul 23. Eur J Pharmacol. 2023. PMID: 37490949 Review.
Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs.
Al-Rashidi RR, Noraldeen SAM, Kareem AK, Mahmoud AK, Kadhum WR, Ramírez-Coronel AA, Iswanto AH, Obaid RF, Jalil AT, Mustafa YF, Nabavi N, Wang Y, Wang L. Al-Rashidi RR, et al. Among authors: nabavi n. Pharmacol Res. 2023 Aug;194:106775. doi: 10.1016/j.phrs.2023.106775. Epub 2023 Apr 17. Pharmacol Res. 2023. PMID: 37075872 Free article. Review.
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.
Rezaee A, Tehrany PM, Tirabadi FJ, Sanadgol N, Karimi AS, Ajdari A, Eydivandi S, Etemad S, Rajabi R, Rahmanian P, Khorrami R, Nabavi N, Aref AR, Fan X, Zou R, Rashidi M, Zandieh MA, Hushmandi K. Rezaee A, et al. Among authors: nabavi n. Biomed Pharmacother. 2023 Sep;165:115187. doi: 10.1016/j.biopha.2023.115187. Epub 2023 Jul 25. Biomed Pharmacother. 2023. PMID: 37499452 Free article. Review.
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Hashemi M, et al. Among authors: nabavi n. Biomed Pharmacother. 2023 Apr;160:114392. doi: 10.1016/j.biopha.2023.114392. Epub 2023 Feb 15. Biomed Pharmacother. 2023. PMID: 36804123 Free article. Review.
62 results